Literature DB >> 26604631

Gallbladder carcinoma: Prognostic factors and therapeutic options.

Thorsten Oliver Goetze1.   

Abstract

The outcome of gallbladder carcinoma is poor, and the overall 5-year survival rate is less than 5%. In early-stage disease, a 5-year survival rate up to 75% can be achieved if stage-adjusted therapy is performed. There is wide geographic variability in the frequency of gallbladder carcinoma, which can only be explained by an interaction between genetic factors and their alteration. Gallstones and chronic cholecystitis are important risk factors in the formation of gallbladder malignancies. Factors such as chronic bacterial infection, primary sclerosing cholangitis, an anomalous junction of the pancreaticobiliary duct, and several types of gallbladder polyps are associated with a higher risk of gallbladder cancer. There is also an interesting correlation between risk factors and the histological type of cancer. However, despite theoretical risk factors, only a third of gallbladder carcinomas are recognized preoperatively. In most patients, the tumor is diagnosed by the pathologist after a routine cholecystectomy for a benign disease and is termed ''incidental or occult gallbladder carcinoma'' (IGBC). A cholecystectomy is performed frequently due to the minimal invasiveness of the laparoscopic technique. Therefore, the postoperative diagnosis of potentially curable early-stage disease is more frequent. A second radical re-resection to complete a radical cholecystectomy is required for several IGBCs. However, the literature and guidelines used in different countries differ regarding the radicality or T-stage criteria for performing a radical cholecystectomy. The NCCN guidelines and data from the German registry (GR), which records the largest number of incidental gallbladder carcinomas in Europe, indicate that carcinomas infiltrating the muscularis propria or beyond require radical surgery. According to GR data and current literature, a wedge resection with a combined dissection of the lymph nodes of the hepatoduodenal ligament is adequate for T1b and T2 carcinomas. The reason for a radical cholecystectomy after simple CE in a formally R0 situation is either occult invasion or hepatic spread with unknown lymphogenic dissemination. Unfortunately, there are diverse interpretations and practices regarding stage-adjusted therapy for gallbladder carcinoma. The current data suggest that more radical therapy is warranted.

Entities:  

Keywords:  Cholecystitis; Gallbladder carcinoma; Gallbladder polyps; Gallstones; Laparoscopic cholecystectomy; Radical cholecystectomy; Stage-adjusted therapy

Mesh:

Year:  2015        PMID: 26604631      PMCID: PMC4649107          DOI: 10.3748/wjg.v21.i43.12211

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  74 in total

1.  Carcinoma in the porcelain gallbladder: a relationship revisited.

Authors:  A E Stephen; D L Berger
Journal:  Surgery       Date:  2001-06       Impact factor: 3.982

2.  Carcinoma of the gallbladder: a study of its modes of spread.

Authors:  R B FAHIM; J R McDONALD; J C RICHARDS; D O FERRIS
Journal:  Ann Surg       Date:  1962-07       Impact factor: 12.969

3.  Adequate extent in radical re-resection of incidental gallbladder carcinoma: analysis of the German Registry.

Authors:  Thorsten Oliver Goetze; Vittorio Paolucci
Journal:  Surg Endosc       Date:  2010-02-23       Impact factor: 4.584

4.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

5.  [Incidental T1b-T3 gallbladder carcinoma. Extended cholecystectomy as an underestimated prognostic factor-results of the German registry].

Authors:  T O Goetze; V Paolucci
Journal:  Chirurg       Date:  2014-02       Impact factor: 0.955

Review 6.  Laparoscopic cholecystectomy and unsuspected gallbladder cancer.

Authors:  F Romano; C Franciosi; R Caprotti; S De Fina; G Porta; G Visintini; F Uggeri
Journal:  Eur J Surg Oncol       Date:  2001-04       Impact factor: 4.424

7.  K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China.

Authors:  Asif Rashid; Takashi Ueki; Yu-Tang Gao; Patrick Scott Houlihan; Charita Wallace; Bing-Sheng Wang; Ming-Chang Shen; Jie Deng; Ann W Hsing
Journal:  Clin Cancer Res       Date:  2002-10       Impact factor: 12.531

8.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

9.  Gene expression profiles in gallbladder cancer: the close genetic similarity seen for early and advanced gallbladder cancers may explain the poor prognosis.

Authors:  Ji Hyang Kim; Han Na Kim; Kyu Taek Lee; Jong Kyun Lee; Seong-Ho Choi; Seung Woon Paik; Jong Chul Rhee; Anson W Lowe
Journal:  Tumour Biol       Date:  2008-05-23

10.  Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for a metaplasia-dysplasia-carcinoma sequence.

Authors:  Jason T Lewis; Jayant A Talwalkar; Charles B Rosen; Thomas C Smyrk; Susan C Abraham
Journal:  Am J Surg Pathol       Date:  2007-06       Impact factor: 6.394

View more
  61 in total

1.  Factors that Minimize Curative Resection for Gallbladder Adenocarcinoma: an Analysis of Clinical Decision-Making and Survival.

Authors:  Breanna C Perlmutter; Robert Naples; Asif Hitawala; John McMichael; Pravallika Chadalavada; Vinay Padbidri; Abdo Haddad; Robert Simon; R Matthew Walsh; Toms Augustin
Journal:  J Gastrointest Surg       Date:  2021-02-09       Impact factor: 3.452

Review 2.  Staging, Treatment, and Future Approaches of Gallbladder Carcinoma.

Authors:  Sanjeev Kumar Shukla; Govind Singh; K S Shahi; Prabhat Pant
Journal:  J Gastrointest Cancer       Date:  2018-03

Review 3.  Gender Differences in Obesity-Related Cancers.

Authors:  Georgia Argyrakopoulou; Maria Dalamaga; Nikolaos Spyrou; Alexander Kokkinos
Journal:  Curr Obes Rep       Date:  2021-02-01

4.  miR-433 accelerates acquired chemoresistance of gallbladder cancer cells by targeting cyclin M.

Authors:  Jianhua Yu; Weiguang Zhang; Baochun Lu; Hongwei Qian; Haijun Tang; Zhiyang Zhu; Xinggui Yuan; Peitu Ren
Journal:  Oncol Lett       Date:  2017-12-28       Impact factor: 2.967

5.  MicroRNA-181b blocks gensenoside Rg3-mediated tumor suppression of gallbladder carcinoma by promoting autophagy flux via CREBRF/CREB3 pathway.

Authors:  Keren Wu; Jie Huang; Tao Xu; Zhipeng Ye; Fa Jin; Ning Li; Bin Lv
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

6.  UCP2 promotes proliferation and chemoresistance through regulating the NF-κB/β-catenin axis and mitochondrial ROS in gallbladder cancer.

Authors:  Jianhua Yu; Lawrence Shi; Weiguo Lin; Baochun Lu; Yunfeng Zhao
Journal:  Biochem Pharmacol       Date:  2019-12-05       Impact factor: 5.858

7.  Overexpression of LncRNA-ROR predicts a poor outcome in gallbladder cancer patients and promotes the tumor cells proliferation, migration, and invasion.

Authors:  Shou-Hua Wang; Ming-Di Zhang; Xiao-Cai Wu; Ming-Zhe Weng; Di Zhou; Zhi-Wei Quan
Journal:  Tumour Biol       Date:  2016-07-23

8.  Defining the Chance of Statistical Cure Among Patients with Extrahepatic Biliary Tract Cancer.

Authors:  Gaya Spolverato; Fabio Bagante; Cecilia G Ethun; George Poultsides; Thuy Tran; Kamran Idrees; Chelsea A Isom; Ryan C Fields; Bradley Krasnick; Emily Winslow; Clifford Cho; Robert C G Martin; Charles R Scoggins; Perry Shen; Harveshp D Mogal; Carl Schmidt; Eliza Beal; Ioannis Hatzaras; Rivfka Shenoy; Shishir K Maithel; Timothy M Pawlik
Journal:  World J Surg       Date:  2017-01       Impact factor: 3.352

9.  Effectiveness of Olaparib Treatment in a Patient with Gallbladder Cancer with an ATM-Inactivating Mutation.

Authors:  Wei Zhang; Junping Shi; Rentao Li; Zhiqiang Han; Ling Li; Guanghao Li; Bo Yang; Qiang Yin; Yingying Wang; Yan Ke; Qiang Li
Journal:  Oncologist       Date:  2020-02-11

Review 10.  AFAP1-AS1: A novel oncogenic long non-coding RNA in human cancers.

Authors:  Fuyou Zhang; Jianfa Li; Huizhong Xiao; Yifan Zou; Yuchen Liu; Weiren Huang
Journal:  Cell Prolif       Date:  2017-10-22       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.